Skip to main content

Table 2 Glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), AST and ALT levels at baseline and at weeks 4 and 12 after treatment

From: The glucose-lowering effect of low-dose diacerein and its responsiveness metabolic markers in uncontrolled diabetes

  Diacerein group
(n = 18)
Placebo group
(n = 17)
HbA1c (%)
 Baseline 8.4 ± 0.1 8.5 ± 0.2
 Week 4 8.1 ± 0.2 (p = 0.14) 8.5 ± 0.1 (p = 0.76)
 Week 12 7.8 ± 0.2 (p < 0.05) 8.2 ± 0.2 (p = 0.06)
FPG (mg/dL)
 Baseline 162.9 ± 8.7 165.9 ± 10.7
 Week 4 164.4 ± 9.9 (p = 0.88) 164.4 ± 9.9 (p = 0.88)
 Week 12 144.0 ± 0.9 (p = 0.06) 161.9 ± 13.6 (p = 0.63)
AST (U/L)
 Baseline 29.3 ± 2.9 36.5 ± 3.4
 Week 4 28.8 ± 3.0 (p = 0.76) 36.1 ± 3.1 (p = 0.90)
 Week 12 24.9 ± 2.1 (p = 0.08) 37.6 ± 3.4 (p = 0.69)
ALT (U/L)
 Baseline 28.4 ± 2.2 28.5 ± 1.5
 Week 4 27.9 ± 2.0 (p = 0.65) 32.5 ± 3.2 (p = 0.18)
 Week 12 26.0 ± 1.7 (p = 0.11) 31.6 ± 1.7 (p = 0.09)
  1. Values are shown as mean ± SE unless otherwise indicated
  2. P-values are versus baseline